Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Lorlatinib Versus Crizotinib in Patients With Advanced
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07633626 (Potential Effect of Vortioxetine on Cognitive Functioning of Patients With ALK-positive Non-Small Cell Lung Cancer Treated With Lorlatinib), which is not on this map. Cited by 220 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Potential Effect of Vortioxetine on Cognitive Functioning of Patients With ALK-positive Non-Small Cell Lung Cancer Treated With Lorlatinib
Who cites it
220 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures.International journal of clinical pharmacy · 2026Pooled it
- Pooled it
- A meta-analysis of the impact of different ALK variants on targeted therapy efficacy in advanced non-small cell lung cancer.Frontiers in oncology · 2026Pooled it
- Neurocognitive outcomes in patients with brain metastases: a systematic review.The Lancet. Oncology · 2025Pooled it
- Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Pooled it
- Phase IV clinical trials for the treatment of non-small cell lung carcinoma (NSCLC): A systemic review from 2020-2025.Saudi medical journal · 2025Pooled it
- [Clinical Practice Guidelines for the Management of Brain Metastases from Non-small Cell Lung Cancer with Actionable Gene Alterations in China (2025 Edition)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Guideline
- Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis.Frontiers in oncology · 2025Pooled it
- Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study.Breast cancer research : BCR · 2026Trial
- Lorlatinib in patients withFuture oncology (London, England) · 2026Trial
- Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.Future oncology (London, England) · 2025Trial
- Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study.The oncologist · 2025Trial
- Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.Lung cancer management · 2026Article
- Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.Lung cancer management · 2026Article
- Curative Oligometastatic Radiation Therapy: Why We Should Redefine Intent When Cure May Be Attainable.Advances in radiation oncology · 2026Article
- Real-world evolution of first-line ALK-positive NSCLC management in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes.Journal of comparative effectiveness research · 2026Article
- Patient and Caregiver Reported Barriers to Cancer Clinical Trial Participation: A Scoping Review.Cancer reports (Hoboken, N.J.) · 2026Article
- Observational
- Living WithJTO clinical and research reports · 2026Article
160 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced,
methodsTwo hundred ninety-six patients with
resultsWith a median follow-up for PFS of 60.2 and 55.1 months, respectively, median PFS was not reached (NR [95% CI, 64.3 to NR]) with lorlatinib and 9.1 months (95% CI, 7.4 to 10.9) with crizotinib (hazard ratio [HR], 0.19 [95% CI, 0.13 to 0.27]); 5-year PFS was 60% (95% CI, 51 to 68) and 8% (95% CI, 3 to 14), respectively. Median time to intracranial progression was NR (95% CI, NR to NR) with lorlatinib and 16.4 months (95% CI, 12.7 to 21.9) with crizotinib (HR, 0.06 [95% CI, 0.03 to 0.12]). Safety profile was consistent with that in prior analyses. Emerging new
conclusionAfter 5 years of follow-up, median PFS has yet to be reached in the lorlatinib group, corresponding to the longest PFS ever reported with any single-agent molecular targeted treatment in advanced NSCLC and across all metastatic solid tumors. These results coupled with prolonged intracranial efficacy and absence of new safety signals represent an unprecedented outcome for patients with advanced
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.